Contact Us
Drug Search Results
More Filters [+]

Dexpramipexole

Alternative Names: dexpramipexole, kns-760704, kns760704, kns 760704
Latest Update: 2025-01-08
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Unknown

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Knopp Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dexpramipexole

Countries in Clinic: Argentina, Austria, Brazil, Bulgaria, Canada, Colombia, Croatia, Czech Republic, France, Georgia, Germany, Hungary, Italy, Korea, Lithuania, Macedonia, Mexico, Poland, Puerto Rico, Romania, Serbia, South Africa, South Korea, Spain, Taiwan, Ukraine, United Kingdom, United States

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Asthma|Pulmonary Eosinophilia

Phase 2: Chronic Obstructive Pulmonary Disease

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
EXHALE-5

P3

Enrolling by invitation

Pulmonary Eosinophilia|Asthma

2027-06-01

AR-DEX-22-04

P3

Unknown Status

Asthma

2027-02-20

jRCT2031240072

P3

Not yet recruiting

Asthma

2026-12-11

AR-DEX-22-01

P3

Unknown Status

Asthma

2026-07-27

Recent News Events

Date

Type

Title

01/09/2025

News Article

 Areteia Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday January 14, 2025

02/15/2024

News Article

 Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

02/01/2024

PubMed

 Chronic rhinosinusitis with nasal polyps: eosinophils versus B lymphocytes in disease pathogenesis.

01/03/2024

News Article

 Areteia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024

11/01/2023

PubMed

 Refashioning dexpramipexole: A new horizon in eosinophilic asthma?

09/25/2023

PubMed

 The FDA-approved compound, pramipexole and the clinical-stage investigational drug, dexpramipexole, reverse chronic allodynia from sciatic nerve damage in mice, and alter IL-1beta and IL-10 expression from immune cell culture.

08/03/2023

News Article

 Areteia Therapeutics Announces Publication of Phase II Data of Oral Dexpramipexole in Eosinophilic Asthma

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions